U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Entacapone/Carbidopa/Levodopa (marketed as Stalevo) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Entacapone/Carbidopa/Levodopa (marketed as Stalevo) Information

Stalevo contains the active ingredients (entacapone, carbidopa and levodopa) and is indicated to treat patients with idiopathic Parkinson's disease:

1. To substitute (with equivalent strength of each of the active ingredients) for immediate-release carbidopa/levodopa and entacapone previously administered as individual products.

2. To replace immediate-release carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" (only for patients taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias).

 


Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax, using the contact information at the bottom of this sheet.  

Related Information

Labeling and Regulatory History from Drugs@FDA